Welcome to our dedicated page for Stoke Therapeutics SEC filings (Ticker: STOK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Stoke Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Stoke Therapeutics's regulatory disclosures and financial reporting.
Stoke Therapeutics is a late-stage RNA medicines company using its proprietary TANGO antisense platform to upregulate protein expression for severe genetic diseases, especially autosomal dominant haploinsufficiencies of the central nervous system and eye.
The lead candidate, zorevunersen (STK-001), targets Dravet syndrome and is in the global Phase 3 EMPEROR trial, aiming to enroll about 150 patients, with pivotal data expected in mid‑2027 and a rolling NDA planned in 2027. Earlier Phase 1/2a and extension studies showed substantial, durable convulsive seizure reductions and improvements in cognition and behavior on top of standard anti‑seizure medicines, with zorevunersen generally well tolerated and holding FDA Breakthrough Therapy Designation.
The second clinical program, STK‑002 for autosomal dominant optic atrophy, is in the Phase 1 OSPREY trial after demonstrating preclinical proof‑of‑concept in restoring OPA1 protein and mitochondrial function. Stoke reports a broad TANGO-driven pipeline, a multijurisdictional patent estate extending into the 2030s–2040s, and major collaborations, including a $60 million upfront deal with Acadia around SYNGAP1 and a $165 million upfront global development and ex‑U.S. commercialization partnership with Biogen for zorevunersen.
Stoke Therapeutics Interim Executive Chair Arthur Tzianabos reported an option exercise and share sale involving the company’s common stock. On March 10, 2026, he exercised stock options to acquire 3,955 shares of common stock at an exercise price of $8.33 per share. The same day, he sold 4,355 common shares at a weighted average price of $40.0033 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on August 15, 2025. Following these transactions, he directly holds 31,339 common shares and retains 118,696 stock options that are fully vested and exercisable and expire on March 19, 2034.
Stoke Therapeutics, Inc. director Adrian R. Krainer reported an open-market sale of 33,243 shares of common stock on March 10, 2026 at a weighted average price of $39.7366 per share. After this transaction, he directly holds 283,302 shares.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 15, 2025, meaning the trades were scheduled in advance rather than timed discretionarily.
Morgan Stanley Smith Barney LLC Executive Financial Services58,769 shares dated 03/10/2026 labeled “Exercise of Stock Options” and 31,739 shares dated 02/13/2024 labeled “Previously Exercised Stock Options.”
The entries are presented as filings of shares to be sold under Rule 144; the excerpt does not state the offering methods, proceeds treatment, or timing beyond the listed dates.
Stoke Therapeutics director Adrian R. Krainer sold 7,229 shares of common stock in an open-market transaction on March 2, 2026 at a weighted average price of $39.6618 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on August 15, 2025, and he now holds 316,545 shares directly.
Stoke Therapeutics, Inc. reported that its Board of Directors approved a discretionary cash bonus of $697,125 for Chief Executive Officer Ian F. Smith. He did not participate in the company’s 2025 annual bonus program, and this bonus equals his full target annual bonus for that year.
The Board based the award on Stoke’s clinical and financial performance following Smith’s appointment as interim CEO in March 2025 and permanent CEO in October 2025. For the 2025 annual bonus program, the Board determined that corporate goal achievement for the company was 150% of target.
Ticho Barry reported acquisition or exercise transactions in this Form 4 filing.
Stoke Therapeutics’ chief medical officer, Barry Ticho, reported equity awards rather than open‑market trades. He was granted options to purchase 60,000 shares of common stock and 40,000 restricted stock units. The option vests monthly over four years starting March 15, 2026, while the RSUs vest in four annual tranches beginning February 15, 2027, in each case conditioned on continued service.
Stoke Therapeutics reported that Chief Executive Officer Ian F. Smith received new equity awards in the form of options and restricted stock units. He was granted 193,000 employee stock options with an exercise right to buy company shares, which vest monthly over four years starting March 15, 2026, contingent on continued service. He also received 129,000 restricted stock units, each representing a right to one share of common stock, vesting in four annual tranches beginning February 15, 2027, also subject to his continued service.